Evolution over time in the cost-effectiveness of pneumococcal conjugate vaccine (PCV13) in older Australians due to herd protection from infant vaccination

In many settings, serotype changes as a result of infant 13-valent pneumococcal conjugate vaccine (PCV13) programs are likely to continue after the introduction of adult PCV13 programs. We applied a multi-cohort model to explore how potential serotype changes may impact on the cost-effectiveness of...

Full description

Saved in:

Bibliographic Details
Published in:	Vaccine Vol. 36; no. 16; pp. 2057 - 2060
Main Authors:	Chen, C., Beutels, P., Newall, A.T.
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier Ltd 12-04-2018 Elsevier Limited
Subjects:	Adults Age Babies Cost analysis Disease Evolution of serotype Herd immunity Immunization Infants Markov model Older people PCV13 Pharmaceuticals Pneumonia Serotypes Streptococcus infections Vaccination Vaccines England United Kingdom > UK Australia New South Wales Australia Herd immunity PCV13 Pneumonia Immunization Markov model Evolution of serotype
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!